Search Results
Your search for The A,The A matches 32360 pages
Showing 22701 - 22750ASTRO Expands Its Advocacy and Government Relations Team With New Assistant Director
The American Society for Radiation Oncology (ASTRO) recently welcomed Stephanie Quinn as its Assistant Director of Congressional Relations, a key position on the Society’s government relations and advocacy team. As ASTRO’s chief liaison to Capitol Hill, Ms. Quinn will lead efforts to educate...
Geriatric Assessment of Transplant-Ineligible Older Adults With Multiple Myeloma: A Novel Approach in the Era of Novel Agents
Myeloma is a disease of aging, with a median age at diagnosis in the United States of 69 years.1 As the population ages, forecasts estimate that, within 20 years, 3 of every 4 people diagnosed with multiple myeloma in the United States will be between the ages of 64 and 84 years.2 In anticipation...
2016 ASH-AMFDP Scholars to Study Malaria, Immunotherapy for Hematologic Malignancies
The American Society of Hematology (ASH) is pleased to announce that Natasha Archer, MD, MPH, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Rayne Rouce, MD, of Baylor College of Medicine, have been selected to participate in the American Society of Hematology-Harold Amos...
Is This the Dawn of Cancer Biosimilars?
The Patient Protection and Affordable Care Act, signed into law in 2010, did more than make it possible for millions of Americans to afford health care; it also established an abbreviated approval pathway for biologic products that are “biosimilar” to, or shown to be “interchangeable” with, a U.S....
Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
On February 26, 2016, obinutuzumab (Gazyva) was approved for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for treatment of patients with follicular lymphoma who have relapsed after or are refractory to a rituximab (Rituxan)-containing regimen.1,2...
Two Types of Asparaginase Compared in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia
Intravenous pegylated (PEG) Escherichia coli (E coli) asparaginase was associated with similar toxicity and efficacy compared with intramuscular native E coli L-asparaginase in children with newly diagnosed acute lymphoblastic leukemia, according to the results of a phase III trial (DFCI 05-001).1 ...
Scandinavian Sarcoma Group Trial Shows Continued Benefit With 3 Years vs 1 Year of Adjuvant Imatinib in High-Risk GIST
As reported in the Journal of Clinical Oncology by Heikki Joensuu, MD, PhD, of the Comprehensive Cancer Center Helsinki, Finland, and colleagues, the second planned analysis in the Scandinavian Sarcoma Group XVIII/AIO trial showed a recurrence-free survival benefit and a continued overall survival ...
No Apparent Benefit of Long-Term Mifepristone in the Treatment of Unresectable Meningioma
In a phase III trial (SWOG S9005) reported in the Journal of Clinical Oncology,1 YongLi Ji, MD, PhD, and Claire Verschraegen, MD, of the University of Vermont Cancer Center; and colleagues found no benefit of treatment with the antiprogestin agent mifepristone vs placebo in patients with...
Study Finds Correlation Between Number of Drug Suppliers and Drug Shortages
Astudy published in the Journal of Oncology Practice1 found that individual drugs with fewer suppliers were associated with an increased likelihood of shortages compared to drugs with a large number of suppliers. The article titled, “Association between the Number of Suppliers for Critical...
Conquering Cancer With Dr. Kim
There are many different ways to treat cancer: surgery, radiation therapy, chemotherapy, and more, sometimes used alone and sometimes in combination. But, in certain circumstances, the best treatment option for a patient may not look much like treatment at all. Instead of attempting to eliminate...
ASCO University® Launches New Certificate Programs for Advanced Practitioners
The role of advanced practitioners in oncology is growing as the demand for team-based care increases—and with that growth comes a need for training materials specifically tailored to this group. ASCO University®, ASCO’s home for lifelong learning, has collaborated with the Association of Physician ...
Direct Your Patients to Cancer.Net for Patient-Friendly Videos
Check out some of the newest Cancer.Net patient-friendly videos produced by ASCO. New topics include an introduction to sarcoma, brain tumors, and managing the side effects of chemotherapy. These videos give people with cancer and their families and friends an additional option for receiving...
Join the Conversation Online at jgo.org
Journal of Global Oncology now offers readers the option to comment on any JGO article. Users can sign in through social media or a Disqus account and share their thoughts with the JGO community. All comments will be moderated by the journal to ensure they are constructive and relevant. Start a...
2016 Pre–Annual Meeting Educational Programs Feature Important Topics for Modern Cancer Care Providers
For oncology professionals looking to maximize their learning and networking opportunities, ASCO will be offering two types of Pre–Annual Meeting Educational Programs ahead of its 2016 Annual Meeting in Chicago this summer. Offered since 2012, Pre–Annual Meeting Seminars are a series of in-depth...
Palbociclib Combined With Fulvestrant in Advanced Breast Cancer Progressing After Endocrine Therapy
On February 19, 2016, palbociclib (Ibrance) was approved for use in combination with fulvestrant (Faslodex) for treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.1,2 In February 2015, palbociclib in...
Cancer Survivorship Research: Learning From the Past to Improve Future Outcomes
Soon after effective therapies for some childhood malignancies were first identified, early leaders in our field had concerns about what would happen to surviving patients as they aged. In 1975, Giulio D’Angio, MD, one of the founders of modern pediatric radiation oncology, presciently called for...
Reduction in Late Mortality in Childhood Cancer Survivors
In a study reported in The New England Journal of Medicine, Gregory T. Armstrong, MD, MSCE, of St. Jude Children’s Research Hospital, Memphis, and colleagues found that late mortality has decreased over time among 5-year survivors of childhood cancer in the Childhood Cancer Survivor Study cohort.1...
Two Fellows Selected for ASCO’s Inaugural Health Policy Fellowship Program
ASCO has announced the two physicians selected for its new Health Policy Fellowship, which kicked off this past October. Robert M. Daly, MD, and Steve Y. Lee, MD, will be the fellows for the inaugural class, which runs from July 1, 2016, to July 1, 2017. The program, aimed at oncologists in the...
Douglas A. Levine, MD, FACOG, FACS, Appointed Director of Gynecologic Oncology at NYU Langone
Douglas A. Levine, MD, FACOG, FACS, will join the faculty of NYU Langone Medical Center as Director of the Division of Gynecologic Oncology at its Laura and Isaac Perlmutter Cancer Center and the Department of Obstetrics and Gynecology, effective May 15, 2016. Dr. Levine brings an exceptional...
Robert Seeger, MD, Awarded Lifetime Achievement Award From Pediatric Blood and Marrow Transplant Consortium
Robert Seeger, MD, Division Head for Basic and Translational Research of the Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles (CHLA), has been selected for the 2016 Lifetime Achievement Award from the Pediatric Blood and Marrow Transplant Consortium (PBMTC). As the eighth...
Laurie H. Glimcher, MD, Named President of Dana-Farber Cancer Institute
Laurie H. Glimcher, MD, an internationally recognized immunologist, has been named the next president and CEO of the Dana-Farber Cancer Institute. Dr. Glimcher is currently the Stephen and Suzanne Weiss Dean of the Medical College at Weill Cornell Medicine in New York, where she is also Professor...
Everolimus in Advanced Neuroendocrine Tumors
On February 26, 2016, everolimus (Afinitor) was approved for treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable, locally advanced, or metastatic.1,2 The drug was previously approved for...
Expert Point of View: David Raben, MD
“Proton therapy may very well offer reduced late toxicities. Reflecting back on past reirradiation studies both within and outside of the cooperative groups, it seems that the late toxicities in this retrospective study were somewhat similar,” said David Raben, MD, Professor of Radiation Oncology...
Markedly Improved Toxicity Rates With Proton-Beam Reirradiation for Recurrent Head and Neck Cancer
Proton-beam radiation therapy may be an attractive option for reirradiation of recurrent head and neck cancer, with encouraging disease control and survival rates and improved toxicity rates compared to photon reirradiation, according to John Han-Chih Chang, MD. Most head and neck cancers present...
Expert Point of View: David Raben, MD
“As radiation oncologists, we have pushed some important envelopes to try to mitigate long-term toxicity,” said David Raben, MD, Professor of Radiation Oncology at the University of Colorado Cancer Center, Aurora, Colorado. “We’ve been able to utilize intensity-modulated radiation techniques to...
Late Toxicity Improved With Response-Adapted Volume De-escalation in Locally Advanced Head and Neck Cancer
Efforts to reduce the late toxicity associated with chemoradiotherapy for locally advanced head and neck squamous cell cancer have focused on radiation therapy dose de-escalation in select populations, according to James Melotek, MD, a radiation oncologist at the University of Chicago. “Patients...
Expert Point of View: Brian Nussenbaum, MD
“This is really the dawn of a new era in the treatment of head and neck cancer, particularly with immunotherapy,” said Brian Nussenbaum, MD, Director of Head and Neck Surgical Oncology at Washington University School of Medicine in St. Louis. According to Dr. Nussenbaum, a better understanding is...
Study Supports an Immune Effect of Chemoradiation in Head and Neck Cancer
Definitive radiation, with or without chemotherapy, induces a combination of immune-stimulating and inhibitory effects in patients with squamous cell carcinoma of the head and neck, according to research presented by Jonathan Schoenfeld, MD, MPhil, MPH, at the 2016 Multidisciplinary Head and Neck...
Mutational Profile May Impact Treatment Decisions for Smokers With Human Papillomavirus–Positive Oropharyngeal Cancer
Smokers whose oropharyngeal tumors are positive for the human papillomavirus (HPV) might need more aggressive treatment for their disease, according to research presented by Jose Zevallos, MD, at the 2016 Multidisciplinary Head and Neck Cancer Symposium in Scottsdale, Arizona.1 Over time,...
Annual Report Cites Continued Decline in Most Cancer Mortality but Trends Toward Increased Liver Cancer Incidence, Mortality
Earlier this month, experts from four major institutions issued the annual Report to the Nation on the Status of Cancer (1975–2012). This year’s report showed that death rates continued to decline for all cancers combined, as well as for most cancer sites for men and women of all major racial and...
FDA Approves Obinutuzumab in Follicular Lymphoma
The U.S. Food and Drug Administration (FDA) has approved obinutuzumab (Gazyva), an anti-CD-20 monoclonal antibody, for use in combination with bendamustine (Bendeka, Treanda) followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma who relapsed after, or are...
FDA Approves Everolimus for Neuroendocrine Tumors of GI or Lung Origin
The U.S. Food and Drug Administration (FDA) has approved everolimus (Afinitor), an mTOR inhibitor, for the treatment of adult patients with progressive, well-differentiated nonfunctional neuroendocrine tumors of gastrointestinal (GI) or lung origin with unresectable, locally advanced, or metastatic ...
FDA Approves Crizotinib for ROS1-Positive Metastatic Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration has approved the tyrosine kinase inhibitor crizotinib (Xalkori) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are ROS1-positive. Crizotinib was first approved in 2011 for the treatment of patients whose tumors are ...
SSO 2016: Largest Surgical Oncology Conference Yet
The Society of Surgical Oncology (SSO) Annual Cancer Symposium is not only the largest surgical oncology conference in the world, but the 69th meeting, recently held in Boston, is the group’s largest ever, according to SSO Past President Jeffrey A. Drebin, MD, PhD, the John Rhea Barton Professor...
Surgeons—Yes, Surgeons—Have a Role in Translational Cancer Research
Surgeons are clearly more comfortable in the operating room than the laboratory, but there is a place for them in translational cancer research as well, according to one surgeon who has led cutting-edge research in pancreatic cancer. “Translational studies require access to patients, to tissue, and ...
Phone Triage System Offers Potential to Reduce Patient Visits to the Emergency Department for Cancer Treatment–Related Symptoms
A quality improvement initiative to reduce the reliance of patients on visits to the emergency department for treatment of side effects related to cancer treatment was reported to be highly effective, according to early findings from a new study. 1 The strategy, involving a telephone triage...
Update on CancerLinQ: A Rapid Health-Care Learning System
On March 26, 2013, ASCO announced that it had completed a prototype of CancerLinQ™, the Society’s groundbreaking health information–technology initiative to achieve higher quality, higher value cancer care with better outcomes for patients. At this year’s 2016 ASCO Quality Care Symposium, Robert S. ...
Regulators Embrace Immunotherapy
The Cancer Drug Development Forum exists to provide, as the name implies, a meeting place to bring together academia, the pharmaceutical industry, and most important regulators for full and frank discussions to facilitate anticancer drug development. In the recent past, the Cancer Drug Development...
Anticoagulation in Patients With Cancer: Understanding the Complexities of Prophylaxis and Management
Venous thromboembolic events are more prevalent in patients with cancer than in persons without it. Cancer is associated with a high rate of venous thromboembolism recurrence, bleeding, requirement for long-term anticoagulation, and reduced quality of life. Moreover, thrombosis is the second most...
Chronic Lymphocytic Leukemia: The Golden Drug Only for Golden Agers?
As reviewed in this issue of The ASCO Post, Burger and colleagues recently reported findings of the RESONATE-2 trial of ibrutinib (Imbruvica) vs chlorambucil (Leukeran) as initial therapy for elderly patients with chronic lymphocytic leukemia (CLL).1 The study met its primary endpoint of...
First-Line Ibrutinib Improves Progression-Free and Overall Survival vs Chlorambucil in Older Patients With Chronic Lymphocytic Leukemia
As reported in The New England Journal of Medicine and at the 2015 American Society of Hematology Annual Meeting, Jan A. Burger, MD, PhD, and colleagues found that first-line treatment with the oral Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) improved progression-free and overall...
Neurofeedback Reduces Pain, Increases Quality of Life for Cancer Patients Suffering From Chemotherapy-Induced Neuropathy
A new study from The University of Texas MD Anderson Cancer Center evaluating the use of neurofeedback found a decrease in the experience of chronic pain and an increase in quality of life among patients with neuropathic pain. The study was presented at the annual meeting of the American...
SGO 2016: Advanced Ovarian Cancer Caused by Genetic Mutations Linked to Better PFS and OS Following Treatment Including Bevacizumab
Women with advanced ovarian cancer caused by genetic mutations—including in BRCA1 and BRCA2—lived significantly longer than those who did not have a mutation following treatment with a chemotherapy regimen that included bevacizumab (Avastin). According to a study, those with BRCA1 and a ...
Ga-68 Dotatate PET/CT Improves Detection of Gastroenteropancreatic Neuroendocrine Tumors
In a study reported in the Journal of Clinical Oncology, Sadowski et al found that Ga-68 dotatate positron-emission tomography/computed tomography (PET/CT) improved detection of gastroenteropancreatic neuroendocrine tumors compared with 111In-pentetreotide single-photon emission computed...
Adding Cediranib to Platinum Therapy Increases Progression-Free Survival in Relapsed Platinum-Sensitive Ovarian Cancer
The phase III ICON6 trial showed that adding cediranib to platinum-based therapy increased progression-free survival and toxicity in women with first relapse of platinum-sensitive ovarian cancer, reported Ledermann et al in The Lancet. Study Details In the double-blind trial, 456 women with...
Update of ASCEND-1 Trial Shows Ceritinib Highly Active in ALK-Rearranged NSCLC, Including Intracranial Disease
Updated results of the phase I ASCEND-1 trial, reported by Kim et al in The Lancet Oncology, indicate that the ALK inhibitor ceritinib (Zykadia) produced high response rates in advanced ALK-rearranged non–small cell lung cancer (NSCLC), including intracranial disease, in both patients with...
Global Perspectives on the Integration of Biosimilars Into Oncology Practice
Dr. Robert Rifkin, Medical Director of Biosimilars at US Oncology Research, moderates a roundtable discussion on Global Perspectives on the Integration of Biosimilars into Oncology Practice, held in conjunction with the 2015 American Society of Hematology Annual Meeting in Orlando, Florida....
Families of Cancer Decedents See Early Hospice, ICU Avoidance, and Death Outside the Hospital as Better End-of-Life Care
Families of patients dying with lung or colorectal cancer judged end-of-life care as better when it was less aggressive, involved earlier hospice, avoided intensive care unit (ICU) admission, and included death outside of the hospital, according to a study reported by Wright et al in JAMA. Study...
Long-Term Follow-up of Prospective U.S. Cohorts Shows Reduced Risk of GI Tract Cancers With Regular Aspirin Use
In a long-term follow up of two large U.S. prospective cohorts reported in JAMA Oncology, Cao et al found that regular use of aspirin was associated with a reduced risk of gastrointestinal (GI) tract cancers. In 2015, the U.S. Preventive Services Task Force recommended the use of aspirin in...
No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma
In a phase III trial (ECOG-ACRIN E2805) reported in The Lancet by Haas et al, no benefit of adjuvant VEGFR (vascular endothelial growth factor receptor) inhibitor treatment with sunitinib or sorafenib (Nexavar) was observed vs placebo in patients with completely resected high-risk nonmetastatic...
